Papers/PMID:27322462
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.
EBioMedicine2016The record
3 findings · 1 compound · 3 endpoints
What it reported
How to read these marksWhat moved
3 findings
finasteride — decreases serum prostate-specific antigen
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Before intervention, PSA and serum steroid hormone levels were not statistically different between groups; after intervention, the finasteride group had significantly lower PSA (3.2 ng/mL versus 5.2 ng/mL; P < 0.001) and DHT levels (10 ng/dL versus 27 ng/dL; P < 0.001) and a significantly higher testosterone level (382 ng/dL versus 327 ng/dL; P = 0.04) than the placebo group.”
Quoted verbatim from Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.. - Study
- RCT
- Dose
- 5 mg daily
- Population
- Men with clinically organ-confined prostate cancer (Gleason score 6 or 7) randomized to finasteride or placebo for 4-6 weeks before prostatectomy
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.2016PMID:27322462Permalink
finasteride — increases total testosterone
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Before intervention, PSA and serum steroid hormone levels were not statistically different between groups; after intervention, the finasteride group had significantly lower PSA (3.2 ng/mL versus 5.2 ng/mL; P < 0.001) and DHT levels (10 ng/dL versus 27 ng/dL; P < 0.001) and a significantly higher testosterone level (382 ng/dL versus 327 ng/dL; P = 0.04) than the placebo group.”
Quoted verbatim from Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.. - Study
- RCT
- Dose
- 5 mg daily
- Population
- Men with clinically organ-confined prostate cancer (Gleason score 6 or 7) randomized to finasteride or placebo for 4-6 weeks before prostatectomy
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.2016PMID:27322462Permalink
finasteride — depletes 17beta-hydroxy-5alpha-androstan-3-one
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Before intervention, PSA and serum steroid hormone levels were not statistically different between groups; after intervention, the finasteride group had significantly lower PSA (3.2 ng/mL versus 5.2 ng/mL; P < 0.001) and DHT levels (10 ng/dL versus 27 ng/dL; P < 0.001) and a significantly higher testosterone level (382 ng/dL versus 327 ng/dL; P = 0.04) than the placebo group.”
Quoted verbatim from Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.. - Study
- RCT
- Dose
- 5 mg daily
- Population
- Men with clinically organ-confined prostate cancer randomized to finasteride or placebo for 4-6 weeks before prostatectomy; serum DHT
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.2016PMID:27322462Permalink